NewAmsterdam Pharma Company N.V. reports results for the quarter ended September 30 - Earnings Summary

• NewAmsterdam Pharma Company N.V. reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -61 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 51 cents per share. Wall Street expected results to range from -62 cents to -35 cents per share.

• Revenue rose 5,406.9% to $19.16 million from a year ago; analysts expected $7.34 million.

• NewAmsterdam Pharma Company N.V.'s reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $17.39 million.

• NewAmsterdam Pharma Company N.V. shares had fallen by 18.2% this quarter and lost 43.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for NewAmsterdam Pharma Company N.V. is $53.50, about 62.8% above its last closing price of $19.90

This summary was machine generated from LSEG data November 4 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)